Study of MI078 for postpartum depression
Part of Mental health, Women’s health & pregnancy clinical trials.
This trial tests a new medication, MI078, to see if it can help women with postpartum depression. You may qualify if you are between 18 and 45, have given birth within the last year, and are currently experiencing moderate to severe depression that started in late pregnancy or shortly after delivery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 45 years old.
- You gave birth within the past year.
- Your depression started between the 28th week of pregnancy and 4 weeks after giving birth.
- You are not currently taking antidepressants or other psychiatric medications for more than 14 days in this episode.
- You do not have a history of bipolar disorder, schizophrenia, or schizoaffective disorder.
- You are not currently breastfeeding or are willing to stop during the treatment period.
- You do not have serious medical conditions like severe heart, liver, or kidney problems.
- You are willing to use effective birth control during the trial and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of TMS (brain stimulation) called SAINT for severe depression that started around childbirth. It may help new mothers who are still within a year postpartum and have not found relief from other treatments.
This trial tests an investigational medicine to help mothers with severe depression that started late in pregnancy or shortly after childbirth. It aims to improve mood and overall well-being.
This trial tests a program based on positive psychology to help prevent or reduce postpartum depression. It is offered within the primary healthcare system and focuses on supporting mothers early in pregnancy.
This study tests an experimental medicine for premenstrual dysphoric disorder (PMDD), a severe form of PMS. It is a phase 1 trial, so the main goal is to check the drug's safety and how your body handles it, but it may also help assess its effectiveness.
This trial tests a new type of talk therapy for women who have given birth and are experiencing depression. It aims to see if this treatment can help improve their mood and well-being.
This study tests a new medication called BMS-986511 for adults with major depressive disorder. It aims to see if the drug can help relieve depression symptoms more effectively than a placebo.
Hear when a new Postpartum Depression (PPD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.